APM 2013



The Advanced Process Modelling Forum

June 5-6, 2013, New York

Oral absorption modelling for targeted drug product design

Kazuko Sagawa, Pfizer Sean Bermingham, PSE Solids

Overview



- Background and motivation
- Desired features of an Oral Absorption modelling tool
- Preview of gCOAS, PSE's Oral Absorption modelling tool
- Validation of an Oral Absorption model need for a toolset
- gCOAS roadmap



Background and motivation



Systems-based Pharmaceutics (SbP)





 SbP is a holistic, model-based approach to the development and optimisation of drug manufacture and drug delivery systems



more about SbP in the last talk of today

- A holistic approach is required to eliminate the silo mentality existing in many companies and hence
 - increase R&D efficiency: reduce iterations between and within stages
 - increase effectiveness: move from local optima towards global optimum



An oral absorption modelling tool for SbP





PSE has an extensive track record in developing modelling tools for a wide range of manufacturing processes ...













- ... but not in modelling biological systems
- Explored options for interfacing to existing tools for the modelling of drug delivery systems
 - would work for simulations: given a certain PSD, dose amount, etc. what is the rate of absorption?
 - but the goal of SbP is a holistic, optimisation-based approach where one can specify the desired absorption behaviour, constraints on CU and FFC, and have the optimiser determine the optimal PSD and dose of the drug

gPROMS-based Oral Absorption modelling tool





- For this reason and several other reasons, PSE started the development of a gPROMS-based oral absorption modelling tool with financial and scientific support from Pfizer
- In summary, key reasons to develop a gPROMS-based OA tool
 - optimisation capabilities: reduce trial-and-error approaches
 - efficient solvers allow explicit accounting for the evolving PSD of several phases, i.e. freeform and salt(s)
 - custom modelling capabilities: domain experts can implement own models for transit, permeation, dissolution, etc.
 - ability to integrate with drug manufacture models (gSOLIDS and gCRYSTAL) using the same platform







Desired features of an Oral Absorption modelling tool (user requirements)





- Sufficiently predictive biopharm assessment tool that allows targeted design of
 - drug molecules
 - permeability
 - solubility of various solid forms
 - drug products (dosage form)
 - excipients, e.g. nucleation inhibitors, solubilisation agents, ...
 - PSD
 - dose
- Library of correlations for phenomena
 - dissolution, transit, permeation, nucleation, etc.
- Open framework that allows domain experts to add/modify correlations without vendor involvement
- Integration with manufacturing models



Sensitivity analyses with respect to ...



- ... Physiology parameters
 - patient-to-patient variability
- ... Uncertainty in physical model parameters
 - dissolution kinetics
 - permeation kinetics
 - nucleation and growth kinetics
 - pharmacokinetics

- ... Formulation parameters
 - particle size
 - dose
 - dosing times
 subject to uncertainty
 arising from categories on
 the left



A gPROMS-based Computational Oral Absorption Simulation framework








A gPROMS-based Computational Oral Absorption Simulation framework






gCOAS model framework



Inspired by Sugano <u>framework</u>

K. Sugano, *Expert Opin. Drug Metab. Toxicol.* (2009) **5**(3), pp. 259-293




- Framework populated with models from various sources
 - typically no consensus regarding the right/best model for a phenomenon
- Open model architecture allows users to add/modify models for phenomena



Drug properties





Drug dosed in one form, but can precipitate as other forms

User can specify which species permeate, e.g. API in neutral form only

Stoichiometry of solid phases with respect to liquid phase species

Solubility product for each salt phase

Intrinsic solubility for the freeform

APM2013

Solid phases



- Can handle any number of solid phases
 - typically up to three phases may (co-)exist
 - e.g. for an acid drug: non-sodium salt, sodium salt and freeform
 - at any point in time, one phase may be dissolving whilst another is precipitating
- Solid phases are characterised by their solubility in the GI fluid and their Particle Size Distribution (PSD)
- Evolution of the PSD of the various phases is described using a population balance framework

$$\frac{\P n_{j}(L)V}{\P t} = -V \frac{\P n_{j}(L)G_{j}(L)}{\P L} + f_{V,in}n_{j,in}(L) - f_{V,out}n_{j,out}(L)$$

same framework used in other PSE products CRYSTAL








GI tract and physiology





- Built-in specifications for
 - physiology and segmentation of the GI tract
 - currently 'only' human
 - can be extended to other organisms
 - digestive state: fed or fasted
- Custom option allows for
 - any segmentation of the GI tract
 - complete freedom in specifying segment radii, lengths, residual volumes, pH values, bile concentration, etc.








- Not only of the API in its various forms
 - dissociated, undissociated, bile bound
- But also of water, buffers and bile
- What happens to the volume of the GI tract segments when you take a tablet with a glass of water?

Fluid transit

- nothing, i.e. constant volumes; or
- varying volumes

 variations depend on intake of fluid, wate permeation

- both options implemented
- Need to investigate impact of normally neglected variations in chyme volume on absorption





Dissolution (and growth)





Detailed description of UWL and chemical equilibria





At the solid-liquid interface:


O = {dissolution} + {reaction} + {diffusion}



Permeation through the intestine wall







- The GI_tract model allows four options for the calculation of effective permeability:
 Permeation
 - Inactive
 - Option 1 (Sugano, 2009)
 - Option 2 (Thelen, 2011)
 - Experimental




Nucleation





 Nucleate after being supersaturated for a given amount of time



Classical nucleation

$$- J_{prim} = \ln A_0 \left(\frac{-16\pi (\alpha \sigma)^3 v_0^2}{3k^3 T^3 \ln S^2} \right)$$

Power law kinetics

$$-J_{prim} = lnk_n \left(\frac{\Delta C}{\rho_c}\right)^n \exp\left(\frac{-E_{A,n}}{RT}\right)$$

- Custom kinetics
 - Allows a domain expert to add a nucleation model
 - E.g., using probability distribution functions of induction time

$$P(t) = 1 - \exp(jV(t - t_g))$$







Nice framework, but where do values for the numerous parameters come from?

Validation of an Oral Absorption model

A supporting modelling tool set for processing experimental data





- Intrinsic solubility or K_{sp}: solubility experiments
- pK_a values: measure dissociation constants using solution-based NMR, ...
- Disintegration & dissolution parameters: in-vitro experiments (e.g. USP-2)
- Nucleation & growth parameters: in-vitro experiments
- Effective permeability
 - LOC-I-GUT experiments → effective permeability directly
 - Oral solution experiments (dissolved API): need to subtract PK effect
 - cell-based (e.g. CaCo-2) experiments → apparent permeability → use LVM model to determine effective permeability
 - Cancer cells of the Colon
 - LVM model to be developed using systems for which loc gut and CaCo-2 data is available

Human PK parameters

- human IV experiments
- correlate to PK parameters from other sources (e.g. animal IV data)
- Fine tune physiology / transit: Clinical data, Cp(t)







gCOAS roadmap

Oral absorption model roadmap



gCOAS v1 (July 2013)

gCOAS v2 (Dec 2013)

- Pharmacokinetics
- Multiple dose (of one API) under feeding regime
- Zwitter ions
- Inclusion of solubilisation technologies

gCOAS v3+

- Controlled release formulations
- Effect of other surfactants
- Longer residence times for colloids and nanoparticles
- Co-crystals

APM2013

Oral absorption modelling tool set roadmap





gCOAS v2 (Dec 2013)

- USP-2 model
- ASD model
- Solubility model

gCOAS v3+

- LOC-I-GUT model
- IV model



Thank you!



APV 2013

The Advanced Process Modelling Forum